Effects of forced diuresis achieved by oral hydration and oral diuretic administration on uroflowmetric parameters and clinical waiting time of patients with lower urinary tract symptoms

被引:5
|
作者
Öztürk, B [1 ]
Çetinkaya, M [1 ]
Öztekin, V [1 ]
Inal, G [1 ]
Adsan, Ö [1 ]
Ugurlu, Ö [1 ]
Özden, C [1 ]
机构
[1] Ankara Numune Educ & Res Hosp, Urol Clin 2, Ankara, Turkey
关键词
diuretics; uroflowmetry; lower urinary tract symptoms;
D O I
10.1159/000071088
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: We studied the impact of diuresis forced by oral hydration or single-dose oral diuretic administration on uroflowmetric parameters and clinical waiting time of patients with lower urinary tract symptoms. Patients and Methods: A total of 58 patients with a mean age of 59 (range 41-77) years who presented with lower urinary tract symptoms were included in the study. The patients were grouped with respect to their International Prostate Symptom Scores as having mild, moderate, or severe symptoms. The prostatic volumes of the patients were calculated using transrectal ultrasound. Uroflowmetric measurements were performed on 3 consecutive days. On the 1st day, the test was performed without diuretic stimulation; on the 2nd day, oral hydration was applied, and on the 3rd day, the patients received 20 mg of furosemide orally. Voiding time, maximum flow rate, voided volume, and the time elapsed in minutes until voiding (waiting time) were recorded. Results: Diuretic stimulation did not significantly alter the uroflowmetric paramesters in each symptom group, but the waiting time was significantly reduced. Forced diuresis caused acute urinary retention in 5 of 20 (25%) severely symptomatic patients. Conclusions: Forced diuresis with oral hydration or oral administration of diuretics improves patient comfort and test applicability by shortening clinical waiting time and reducing the number of attempts to reach the sufficient urine volume for reliable measurements and can be applied safely for mild and moderately symptomatic patients. On the other hand, the risk of 25% of acute urinary retentions should be reconsidered, and the decision about diuretic stimuli should be made carefully by the clinician in severely symptomatic patients. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:22 / 25
页数:4
相关论文
共 21 条
  • [11] The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study
    Fujimoto, Kiyohide
    Hirao, Yoshihiko
    Ohashi, Yasuo
    Shibata, Yasuhiro
    Fuji, Kohzo
    Tsuji, Hidenori
    Miyazawa, Katsuhito
    Ohtani, Mikinobu
    Furuya, Ryoji
    Boku, Eitetsu
    ADVANCES IN UROLOGY, 2013, 2013
  • [13] Efficacy and Safety of Combined Oral Therapy with Tadalafil and Alfuzosin: An Integrated Approach to the Management of Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction. Preliminary Report
    Liguori, Giovanni
    Trombetta, Carlo
    De Giorgi, Gioacchino
    Pomara, Giorgio
    De Giorgi, Giuseppe
    Vecchio, Daniele
    Ocello, Giuseppe
    Ollandini, Giangiacomo
    Bucci, Stefano
    Belgrano, Emanuele
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 (02): : 544 - 552
  • [14] An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Jin, Zhe
    Zhang, Zhi-Chao
    Liu, Ji-Hong
    Lu, Jun
    Tang, Yu-Xin
    Sun, Xiang-Zhou
    Song, Wei-Dong
    Gao, Bing
    Guo, Ying-Lu
    Xin, Zhong-Cheng
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (04) : 630 - 635
  • [15] Effects of α1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review
    Creta, Massimiliano
    Bottone, Francesco
    Sannino, Simone
    Maisto, Enrico
    Franco, Marco
    Mangiapia, Francesco
    La Rocca, Roberto
    Imperatore, Vittorio
    Longo, Nicola
    Vivaldi, Osvaldo
    Fusco, Ferdinando
    MINERVA UROLOGICA E NEFROLOGICA, 2016, 68 (02) : 209 - 221
  • [16] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):: Efficacy and tolerability in a placebo and active comparator controlled phase 3a study
    Chapple, CR
    Al-Shukri, SH
    Gattegno, B
    Holmes, S
    Martínez-Sagarra, JM
    Scarpa, RM
    Trip, OBV
    Vik, V
    van der Putten-Slob, I
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) : 33 - 44
  • [17] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a phase 2b dose-response study
    Chapple, CR
    Lorenz, J
    Mortensen, R
    Pauthner, H
    Reise, MO
    Schulman, CC
    van der Putten-Slob, I
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) : 25 - 32
  • [18] The Sustained Therapeutic Effects of Percutaneous Posterior Tibial Nerve Stimulation in the Treatment of Neurogenic Lower Urinary Tract Symptoms in Patients with Parkinson's Disease: 24-months Clinical and Urodynamic Results
    Kabay, Sahin
    Kabay, Sibel Canbaz
    UROLOGY, 2021, 153 : 49 - 55
  • [19] EFFECTS OF DAILY TADALAFIL 5MG ADMINISTRATION ON POST MICTURITION DRIBBLING (PMD) IN MEN WITH LOWER URINARY TRACT SYMPTOMS: A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL STUDY
    Jeong, H-C
    Ko, K-T
    Kim, K-Y
    Lee, W-K
    Yang, D-Y
    Lee, S-H
    JOURNAL OF SEXUAL MEDICINE, 2019, 16 (05): : S17 - S17
  • [20] Effects of Daily Tadalafil 5mg Administration on Post Micturition Dribbling (PMD) in Men with Lower Urinary Tract Symptoms: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Study
    Yang, Dae Yul
    Ko, Kyungtae
    Jeong, Hyun Cheol
    Lee, Won Ki
    Lee, Seong Ho
    Yang, Sang-Kuk
    Moon, Ki Hak
    INTERNATIONAL JOURNAL OF SEXUAL HEALTH, 2019, 31 : A467 - A467